Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Ofev nintedanib loss of exclusitvity?Contrave exclusivity?Ofev patent expiration europe?Lupin mepolizumab biosimilar?Does medicare cover etravirine?
See the DrugPatentWatch profile for tymlos
Tymlos (abaloparatide) was approved by the U.S. FDA on April 28, 2017. [1]
Tymlos is an injectable osteoporosis treatment indicated to increase bone mass in people at high risk for fracture. [1]
[1] DrugPatentWatch.com – Tymlos (abaloparatide) FDA Approval Date
Other Questions About Tymlos :